January 2020

Cure SMA Adds New Equipment Item for Teens and Adults with SMA

Along with funding SMA research and offering clinical care services, Cure SMA provides thousands of affected individuals and families with vital support and resources that help them navigate daily life with SMA. We are thrilled to add to our equipment pool inventory the Panthera S3 Swing—a lightweight manual wheelchair for adults and teens living with […]

Cure SMA Adds New Equipment Item for Teens and Adults with SMA Read More »

Genentech’s Risdiplam Meets Primary Endpoint in Pivotal FIREFISH Trial in Infants with Type 1 SMA

Genentech, a member of the Roche Group, today announced positive topline results from the pivotal Part 2 of the FIREFISH study, evaluating risdiplam in infants aged 1-7 months with Type 1 spinal muscular atrophy (SMA). The primary outcome measure of the study was the proportion of infants sitting without support for at least five seconds

Genentech’s Risdiplam Meets Primary Endpoint in Pivotal FIREFISH Trial in Infants with Type 1 SMA Read More »

Annual SMA Conference Registration Continues to Grow!

The 2020 Annual SMA Conference registration numbers are growing quickly! We expect the 2020 conference – which includes both the Family Conference and the Research & Clinical Care Meeting – will be one of our biggest ever. Hotel rooms in our block are filling up, so be sure to register and make your hotel reservations

Annual SMA Conference Registration Continues to Grow! Read More »

Community Statement from Scholar Rock Regarding SRK-015

Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today highlighted key accomplishments of the past year and announced R&D priorities for 2020. Below please find a community statement from Scholar Rock specifically discussing SRK-015. ______________________________________________________________________________ Dear SMA Community, We at Scholar

Community Statement from Scholar Rock Regarding SRK-015 Read More »

Cure SMA and Biogen to Co-Host Webinar on DEVOTE Clinical Trial – Register Today!

On Tuesday, February 4th, at 11am CST (9am PST/10am MST/12pm EST) Biogen and Cure SMA will co-host a webinar for the SMA community. During the webinar, you’ll hear from Biogen about the latest information on its SPINRAZA clinical trial, DEVOTE, a Phase 2/3 randomized, controlled dose-escalating study with infantile and later-onset SMA of all ages,

Cure SMA and Biogen to Co-Host Webinar on DEVOTE Clinical Trial – Register Today! Read More »

Scroll to Top